Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer

ABSTRACT Lung cancer patients with leptomeningeal metastases (LMs) suffer from severe clinical symptoms, poor quality of life, narrow diagnostic and therapeutic time windows, low response to standard treatments, short survival periods, and poor prognoses. At present, there is a lack of precise diagn...

Full description

Saved in:
Bibliographic Details
Main Authors: Gen Lin, Yongsheng Wang, Tao Xin, Ding Zhang, Qiuyu Zhang, Yangsi Li, Yudan Chi, Yun Fan, Anwen Liu, Haipeng Xu, Liang Shi, Longfeng Zhang, Qian Miao, Xiaobin Zheng, Lijun Li, Kaijia Zhou, Qiwei Yao, Zihua Zou, Kang Miao, Yaping Hong
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.70088
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850113656556093440
author Gen Lin
Yongsheng Wang
Tao Xin
Ding Zhang
Qiuyu Zhang
Yangsi Li
Yudan Chi
Yun Fan
Anwen Liu
Haipeng Xu
Liang Shi
Longfeng Zhang
Qian Miao
Xiaobin Zheng
Lijun Li
Kaijia Zhou
Qiwei Yao
Zihua Zou
Kang Miao
Yaping Hong
author_facet Gen Lin
Yongsheng Wang
Tao Xin
Ding Zhang
Qiuyu Zhang
Yangsi Li
Yudan Chi
Yun Fan
Anwen Liu
Haipeng Xu
Liang Shi
Longfeng Zhang
Qian Miao
Xiaobin Zheng
Lijun Li
Kaijia Zhou
Qiwei Yao
Zihua Zou
Kang Miao
Yaping Hong
author_sort Gen Lin
collection DOAJ
description ABSTRACT Lung cancer patients with leptomeningeal metastases (LMs) suffer from severe clinical symptoms, poor quality of life, narrow diagnostic and therapeutic time windows, low response to standard treatments, short survival periods, and poor prognoses. At present, there is a lack of precise diagnosis and treatment pathways and relevant consensus for LMs of lung cancer. In order to better guide the clinical diagnosis and treatment of LMs of lung cancer in an early, reasonable, and safe way, the experts of the Neurological Tumor Specialist Committee of the Chinese Society of Clinical Oncology (CSCO) have formulated this consensus based on the actual diagnosis and treatment of LMs of lung cancer in China, with reference to the latest research data, relevant guidelines and consensus, and the experts' clinical experience, as well as the results of experts' polling on the pre‐set issues of LMs. The consensus focuses on diagnosing LMs, stratified management, efficacy evaluation systems, treatment strategies, common complications, and palliative care. It gives recommendations in each of the five aspects to provide clinicians with suggestions and references for diagnosing and treating LMs in lung cancer.
format Article
id doaj-art-a9d45ddb6c2048afa583c63b24f1f076
institution OA Journals
issn 1759-7706
1759-7714
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series Thoracic Cancer
spelling doaj-art-a9d45ddb6c2048afa583c63b24f1f0762025-08-20T02:37:05ZengWileyThoracic Cancer1759-77061759-77142025-06-011611n/an/a10.1111/1759-7714.70088Chinese Expert Consensus on Leptomeningeal Metastases of Lung CancerGen Lin0Yongsheng Wang1Tao Xin2Ding Zhang3Qiuyu Zhang4Yangsi Li5Yudan Chi6Yun Fan7Anwen Liu8Haipeng Xu9Liang Shi10Longfeng Zhang11Qian Miao12Xiaobin Zheng13Lijun Li14Kaijia Zhou15Qiwei Yao16Zihua Zou17Kang Miao18Yaping Hong19Department of Medical Oncology Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University Beijing ChinaDivision of Thoracic Tumor Multimodality Treatment Cancer Center and National Medical Products Administration key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University Chengdu Sichuan ChinaDepartment of Oncology The Second Affiliated Hospital, Harbin Medical University Harbin ChinaDepartment of Pulmonary and Critical Care Medicine Huashan Hospital, Fudan University Shanghai ChinaInstitute of Immunotherapy, School of Basic Medical Sciences, Fujian Medical University Fuzhou ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou Guangdong ChinaInstitute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University Shanghai ChinaDepartment of Thoracic Medical Oncology Zhejiang Cancer Hospital Hangzhou ChinaDepartment of Oncology The Second Affiliated Hospital of Nanchang University Nanchang Jiangxi ChinaDepartment of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou ChinaDepartment of Medical Oncology Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University Beijing ChinaDepartment of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou ChinaDepartment of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou ChinaDepartment of Medical Oncology Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University Beijing ChinaInstitute of Immunotherapy, School of Basic Medical Sciences, Fujian Medical University Fuzhou ChinaDepartment of Neurosurgical Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou ChinaDepartment of Radiation Oncology Fujian Cancer Hospital & Fujian Medical University Cancer Hospital Fuzhou ChinaDepartment of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou ChinaDepartment of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou ChinaDepartment of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou ChinaABSTRACT Lung cancer patients with leptomeningeal metastases (LMs) suffer from severe clinical symptoms, poor quality of life, narrow diagnostic and therapeutic time windows, low response to standard treatments, short survival periods, and poor prognoses. At present, there is a lack of precise diagnosis and treatment pathways and relevant consensus for LMs of lung cancer. In order to better guide the clinical diagnosis and treatment of LMs of lung cancer in an early, reasonable, and safe way, the experts of the Neurological Tumor Specialist Committee of the Chinese Society of Clinical Oncology (CSCO) have formulated this consensus based on the actual diagnosis and treatment of LMs of lung cancer in China, with reference to the latest research data, relevant guidelines and consensus, and the experts' clinical experience, as well as the results of experts' polling on the pre‐set issues of LMs. The consensus focuses on diagnosing LMs, stratified management, efficacy evaluation systems, treatment strategies, common complications, and palliative care. It gives recommendations in each of the five aspects to provide clinicians with suggestions and references for diagnosing and treating LMs in lung cancer.https://doi.org/10.1111/1759-7714.70088expert consensusleptomeningeal metastaseslung cancer
spellingShingle Gen Lin
Yongsheng Wang
Tao Xin
Ding Zhang
Qiuyu Zhang
Yangsi Li
Yudan Chi
Yun Fan
Anwen Liu
Haipeng Xu
Liang Shi
Longfeng Zhang
Qian Miao
Xiaobin Zheng
Lijun Li
Kaijia Zhou
Qiwei Yao
Zihua Zou
Kang Miao
Yaping Hong
Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
Thoracic Cancer
expert consensus
leptomeningeal metastases
lung cancer
title Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
title_full Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
title_fullStr Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
title_full_unstemmed Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
title_short Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer
title_sort chinese expert consensus on leptomeningeal metastases of lung cancer
topic expert consensus
leptomeningeal metastases
lung cancer
url https://doi.org/10.1111/1759-7714.70088
work_keys_str_mv AT genlin chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT yongshengwang chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT taoxin chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT dingzhang chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT qiuyuzhang chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT yangsili chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT yudanchi chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT yunfan chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT anwenliu chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT haipengxu chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT liangshi chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT longfengzhang chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT qianmiao chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT xiaobinzheng chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT lijunli chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT kaijiazhou chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT qiweiyao chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT zihuazou chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT kangmiao chineseexpertconsensusonleptomeningealmetastasesoflungcancer
AT yapinghong chineseexpertconsensusonleptomeningealmetastasesoflungcancer